Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2019
At a glance
- Drugs ALRN 6924 (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia; Hepatoblastoma; Precursor cell lymphoblastic leukaemia-lymphoma; Retinoblastoma; Solid tumours
- Focus Adverse reactions
- 01 Nov 2018 According to an Aileron Therapeutics media release, this trial is being conducted under and agreement between the company and the Dana-Farber/Boston Children's Cancer and Blood Disorders Center.
- 18 Oct 2018 Planned initiation date (anticipated data of first patient enrolment) changed from 30 Sep 2018 to 30 Nov 2018.
- 18 Oct 2018 Planned number of patients changed from 6 to 69.